ABVC Biopharma Inc
ABVC
NASDAQ
Biotechnology
$0.90
USD
-0.06 (-6.20%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $25.23M
Volume 116.8K
Revenue
$795,950
TTM
+103.4%
YoY
Gross Margin
100%
TTM
+0.1%
YoY
Net Income
$-7.60M
TTM
-66.6%
YoY
Operating Cash Flow
$-2.69M
TTM
-29.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | +104.5% | -100.0% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.8 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.3 | 0.8 | 0.0 | 0.8 | 0.8 |
Other Operating Expenses | 0.0 | 1.1 | 0.0 | 0.8 | 0.0 |
Total Operating Expenses | 2.3 | 2.0 | 0.0 | 1.6 | 0.8 |
Operating Income | -2.3 | -1.2 | 0.0 | -1.6 | -0.8 |
EBITDA | -2.3 | -1.2 | 0.0 | -1.6 | -0.8 |
Other Income / Expense | 0.1 | -0.1 | 0.0 | -0.1 | 0.0 |
Total Other Income / Expense | -0.0 | -0.1 | 0.0 | -0.1 | -0.0 |
Income Before Income Taxes | -2.3 | -1.3 | 0.0 | -1.7 | -0.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.3 | -1.3 | -3.8 | -1.7 | -0.8 |
Consolidated Net Income / Loss | -2.3 | -1.3 | 0.0 | -1.7 | -0.8 |
Net Income Attributable to Common Shareholders | -2.3 | -1.2 | 0.0 | -1.6 | -0.7 |
Basic EPS | -$0.13 | -$0.05 | $0.00 | -$0.06 | -$0.03 |
Diluted EPS | -$0.13 | -$0.05 | $0.00 | -$0.06 | -$0.03 |
Basic Shares Outstanding | 17.4M | 23.3M | 24.8M | 25.4M | 26.1M |
Diluted Shares Outstanding | 17.4M | 23.3M | 24.8M | 25.4M | 26.1M |